Kornimate/medical-research-clean huggingface dataset:
assessment of cerebral vasoreactivity using near-infrared spectroscopy (nirs) in infants (varo)

Conditions: Hypercapnia

Summary: the purpose of this study is to show that a permissive hypercapnia during mechanical ventilation in children under general anaesthesia will improve cerebral perfusion.

mechanical ventilation interferes with cerebral perfusion via the changes in intrathoracic pressure and/or as a consequence of hypocapnia. this latter occurs frequently following traditional ventilation strategies with relatively high tidal volume and respiratory rate. new trends in anesthesia intend to promote protective lung ventilation by keeping a normocapnic or even mildly hypercapnic state. however, cerebral vascular vasotonicity is carbon dioxide (co2)-dependent with hypocapnia potentially leading to vasoconstriction and subsequent decrease in cerebral blood flow. changes in cerebral vasoreactivity can be assessed by the near infrared spectroscopy (nirs) device. this monitoring evaluates the changes in various parameters (deoxygenated hemoglobin, oxygenated hemoglobin, the tissue oxygenation index (toi) and the tissue hemoglobin index (thi)) that act as surrogate for cerebral vasoconstriction. we, therefore designed this prospective observational comparative effectiveness study in order to characterize the potential beneficial effect of permissive hypercapnia on cerebral perfusion in infants.

Eligibility criteria:
inclusion criteria: * term neonates during their infancy * for elective surgery requiring general anesthesia and endotracheal intubation exclusion criteria: * all infants with cardiac anomalies, chronic pulmonary disease (bronchopulmonary dysplasia, cystic fibrosis, asthma), pulmonary hypertension or cranial hypertension will be excluded * all infants where no access to the forehead is possible as a consequence of the operating field

Keywords: spectroscopy, near-infrared infant anesthesia, general
detecting recurrent prostate cancer with c-11 choline positron emission tomography: an expanded access study

Conditions: Cancer of the Prostate

Summary: the purpose of this study is to provide clinical access to pet/ct and pet/mri with c-11 choline for evaluation of men with biochemically recurrent prostate cancer while awaiting approval of the washington university abbreviated new drug application for c-11 choline.


Eligibility criteria:
inclusion criteria: 1. patient must have biopsy-proven adenocarcinoma of the prostate initially treated with curative intent (surgery and radiation therapy are most common treatments but other treatments are also eligible). 2. biochemical recurrence defined as any of the following: * psa ≥ 0.2 ng/ml in at least two sequential tests for patients treated with surgery. * psa ≥ 2.0 ng/ml above the post therapy nadir for patients treated with radiation therapy, brachytherapy or cryotherapy. * psa ≥ 2.0 ng/ml above the most recent therapy nadir for patients who have received additional treatment in the recurrent setting. 3. patient must have undergone standard-of-care restaging that does not clearly identify site(s) of active disease. standard staging examinations may include one or more of the following: ct or mri, bone imaging (either tc-99m bisphosphonate scintigraphy or f-18 sodium fluoride pet), or in-111 capromab pendetide scintigraphy. 4. age \> 18 years. 5. patient must be able to tolerate pet/mri or pet/ct imaging 6. patient must be able to understand and willing to sign a written informed consent document. 7. patient must be able to understand and willing to sign an advance beneficiary notice (abn) (medicare patient) or a notice of non-coverage (nnc) from (non-medicare patient) that addresses the potential cost to the patient of c-11 choline pet/ct or pet/mri. exclusion criteria: 1. for patients planned to have pet/mri: * patient must not have claustrophobia or any other contraindication to mri as evaluated by a standardized mri safety questionnaire. * if applicable, patient must not have renal insufficiency (estimated glomerular filtration rate \< 30 ml/min/1.73 m2 based on measurement within the past 60 days) or be undergoing dialysis as these conditions preclude safe administration of mri contrast agents. note: at the discretion of principal investigator, a subject may be allowed to enroll/continue on study and undergo imaging without the administration of contrast in the event of renal insufficiency. * if applicable, patient must not have a known prior reaction to gadolinium based mri contrast agents. 2. for patients planned to have pet/ct: * patient must not have claustrophobia that would preclude pet/ct imaging or other contraindications to ct imaging.

Keywords: recurrent
growth hormone in obese cases with covid-19

Conditions: Covid19

Summary: the use of growth hormone in obese cases with covid-19 may help them to recover earlier.

it is well known that lymphoid organs such the thymus, the spleen and peripheral blood produce growth hormone (gh) and gh receptor is expressed on different subpopulations of lymphocytes. many in vitro and in animal studies demonstrate an important role of gh in immunoregulation. gh stimulates t and b cells proliferation and immunoglobulin synthesis, enhances the maturation of myeloid progenitor cells and is also able to modulate cytokine response. the use of growth hormone in obese cases with covid-19 may help them to recover earlier.

Eligibility criteria:
inclusion criteria: * obese with bmi \> 30 exclusion criteria: * history of hypersensitivity to gh
acupuncture versus placebo acupuncture during in vitro fertilization (ivf) embryo transfer

Conditions: Infertility

Summary: during ivf treatment, acupuncture at the time of embryo transfer may improve the pregnancy rate. this study aims to compare ivf pregnancy between two groups of patients that received either acupuncture or sham acupuncture (placebo)around embryo transfer

acupuncture at the time of embryo transfer may improve the ivf pregnancy rate. this study aims to compare the ivf pregnancy between two groups of patients that undergo ivf/icsi treatment. the patients are randomized to receive either acupuncture or sham acupuncture (placebo)around embryo transfer

Eligibility criteria:
inclusion criteria: * infertility * below 38 years * ivf or icsi treatment * fresh embryo transfer cycle * no more than two earlier embryo transfers with "fresh" embryos * embryo transfer on day 2 or 3 after oocyte aspiration, single or double embryo transfer exclusion criteria: * frozen embryo transfer * oocyte donation * other "alternative" treatment during the cycle

Keywords: infertility ivf acupuncture
effect of motorized cryotherapy on early effusion, swelling, and pain after anterior cruciate ligament reconstruction

Conditions: Cryotherapy Effect

Summary: to test the efficacy of motorized cryotherapy on early effusion, and pain after acl reconstruction

to test the efficacy of motorized cryotherapy on early effusion, and pain after acl reconstruction compared to classical ice bagging

Eligibility criteria:
inclusion criteria: * acute acl ruptured patient exclusion criteria: * combined meniscal injury requiring surgery * combined ligament injury requiring surgery * combined chondral injury requiring surgery * previous surgery history on corresponding knee * allergic to cold
clinical impact of rapid identification of positive blood cultures vs. internal laboratory standard

Conditions: Bloodstream Infections

Summary: in this before-after study, different new methods for bacterial species identification from positive blood cultures will be compared towards historic controls. all samples are analyzed within the routine workflow for bacterial species identification and antibiotic resistance profiling. patients with positive blood cultures from 2016 to 2018 receiving a conventional identification methods (controls) will be compared to patients from 2018 and 2019 with a new identification method (cases). the conventional identification method consisted in general of an over-night subculture and subsequent identification of the bacterial pathogen using either biochemical profiling or matrix-assisted laser-desorption/ionization time-of-flight (maldi-tof ms). the new identification of positive blood cultures methods include (i) either the newly introduced biofire filmarray© blood culture identification (bcid) panel or (ii) in a subset of patients whole genome sequencing (wgs) approaches.


Eligibility criteria:
inclusion criteria: * patients with positive blood cultures hospitalized between august 2016 and october 2019 * documented refusal of the general consent exclusion criteria: * outpatients * patients hospitalized in other hospitals * patients with known bacteremia diagnosed in another hospital

Keywords: maldi-tof ms biofire filmarray© blood culture identification (bcid) panel shotgun metagenomic approach
restoration of atrioventricular synchrony trial

Conditions: First Degree AV Block

Summary: the objective of the trial is to observe the effects of restoring atrioventricular (av) synchrony in subjects with prolonged pr intervals. this will be assessed both acutely and chronically using echocardiographic and functional measurements.

same as above.

Eligibility criteria:
inclusion criteria: * meet current indications for an implantable cardioverter-defibrillator (icd) implant with: * qrs width \< 120 msec * left ventricular ejection fraction (lvef) \< 35% (no more than 180 days prior to enrollment) * nyha functional class ii/iii * optimal pharmacological heart failure therapy * pr interval \>/= 230 msec * ability to tolerate protocol required programming * access to a telephone line compatible with the latitude® communicator * subjects in sinus rhythm at the time of the baseline visit and who are expected to remain in sinus rhythm for the duration of the study * age 18 or above, or of legal age to give informed consent specific to state and national law * willing and capable of providing informed consent, undergoing a device implant, participating in all testing associated with this clinical investigation at an approved clinical investigational center and return to the investigational center at the intervals defined by this protocol exclusion criteria: * previously placed pacemaker, icd, or crt device * inability or refusal to sign the informed consent form * documented life expectancy of less than 12 months or expected to undergo heart transplant within the next 12 months * have tricuspid valve disease or who are likely to receive a mechanical tricuspid valve during the course of the clinical investigation * inability or refusal to comply with the follow-up schedule * have a neuromuscular, orthopedic, or other noncardiac condition that prevents subject from normal unsupported walking for the six minute hall walk test * have surgically uncorrected primary valvular heart disease * second or third degree atrioventricular block (avb) * permanent or persistent atrial tachyarrhythmia that is refractory to all therapies * have had cardiac surgery, percutaneous coronary intervention, or myocardial infarction within 3 months of signing consent or who are likely to undergo a cardiac surgery or procedure in the foreseeable future * enrolled in any concurrent study unless written approval has been obtained from boston scientific or the integra group * women who are pregnant or plan to become pregnant

Keywords: implantable icd first degree av block
glucagon like peptides receptors expression in the stomach of diabetes type 2

Conditions: Diabetes Mellitus Type 2

Summary: glucagon like peptides receptors expression in the stomach of diabetes type 2 glucagon like peptides (glp-1, glp-2), are hormones secreted by l cells located along the gastrointestinal tract. these hormones are secreted after meals and have some roles in regulating the digestion process, absorption, and sending signals to the brain that regulate food consumption. glp peptides affect peripheral targets and have an important homeostatic role. glp-1 decreases the circulatory glucose level and glp-2 has trophic effects which enable adequate intestine growth. we aimed in our study to investigate the glp-1 and glp-2 receptor expression in different zones of the stomach in diabetes type 2 patients. if there are differences, it might explain the pathological gastric emptying in these patients. understanding the function of these peptides may lead to new therapeutic options for diabetic patients with delayed gastric emptying. methods: 20 diabetes type 2 patients with symptoms that need upper endoscopy will be included in the study and 20 controls aged 18-70 years. patients with neurological disease will be excluded. during esophagogastroduodenoscopy 3 biopsies will be taken from the antrum, corpus and cardia. the biopsies will be stored in -70. after rna extraction the glp receptors expression will established by real time pcr method. patients with different expression compared to control will undergo isotopic scan for gastric emptying.


Eligibility criteria:
inclusion criteria: * 20 diabetes type 2 patients with symptoms that need upper endoscopy will be included in the study and 20 controls aged 18-70 years exclusion criteria: * patients with neurological disease will be excluded

Keywords: patients with diabetes mellitus type 2 undergo upper endoscopy biopsies for glp receptors expression pcr analysis
cs1p1 pet studies of neuroinflammation in parkinson disease

Conditions: Parkinson Disease

Summary: parkinson disease (pd) is a progressive neurological disorder strongly linked to advancing age that results in decline in mobility and thinking. based on prior research, the investigators think that small amounts of inflammation in the brain may contribute to the mobility and thinking problems in people with pd. they are trying to measure inflammation in the brain in order to understand how this inflammation could be contributing to the symptoms of pd. this study involves a brain positron emission tomography (pet) scan with a new, investigational radioactive tracer called \[11c\]-cs1p1 to identify inflammation in the brain.the goal of this project is to quantify neuroinflammation with \[11c\]-cs1p1 pet and compare to motor and cognitive function in participants with various stages of severity of pd compared to controls.


Eligibility criteria:
inclusion criteria: * parkinson disease (pd) participants must be at least 50 years old and meet clinical diagnostic criteria of idiopathic pd. * control participants must be at least 50 years old and not have pd, no first-degree family member with pd, and no evidence of pd or dementia on examination. exclusion criteria: * any history of other neurologic illness (e.g. stroke, seizure, multiple sclerosis) * history of brain surgery or major head trauma * major medical/systemic illness * severe psychiatric illness (e.g. bipolar disorder, schizophrenia) * major drug abuse * history of long term use of anti-dopaminergic medication * chronic treatment with immunomodulatory or anti-inflammatory medications * weight over 300 lbs * contraindication to or inability to tolerate mri
phase ii study of the enzyme inhibitor ntbc for tyrosinemia type i

Conditions: Tyrosinemia, Type I

Summary: objectives: assess whether 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (ntbc) at 0.6 mg/kg per day prevents liver failure in at least 1 patient with tyrosinemia type i.

protocol outline: only 2 patients with tyrosinemia type i are known to this research team; others will be treated if found and if clinical conditions permit. the enzyme inhibitor 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (ntbc) is administered orally, in 2 divided doses daily with meals. patients will be followed closely for side effects attributable to ntbc.

Eligibility criteria:
protocol entry criteria: tyrosinemia type i no cirrhosis no hepatocellular carcinoma

Keywords: inborn errors of metabolism rare disease tyrosinemia i
optimal management of malignant dysphagia

Conditions: Malignant Dysphagia; Esophageal Cancer

Summary: according to the canadian cancer society there are approximately 1700 new cases of esophageal cancer per year in canada. as most of these patients are diagnosed in advanced stages of the disease, 1800 deaths are estimated from this cancer annually . progressive dysphagia is the most common presenting symptom and impacts not only the patient's quality of life but the ability to tolerate life prolonging treatments such as systemic chemotherapy. although there are several therapeutic modalities to alleviate malignant dysphagia including laser, photodynamic therapy and cryotherapy , the use of stents and radiotherapy are the most commonly employed. however, the optimal approach to effective, timely treatment of malignant dysphagia remains a challenge. the investigators conducted a preliminary retrospective review to investigate such palliation procedures and found that a multi-modality approach may yield the most favourable results . therefore, our clinical trial will examine the effectiveness of adding a single dose of brachytherapy to patients with severe dysphagia who have already been treated with a endoscopically placed self-expanding metallic stent.


Eligibility criteria:
inclusion criteria: * age ≥18 years * confirmed esophageal/gastroesophageal (gej) cancer (siewert type i and type ii only) of any histology on biopsy * dysphagia score ≥2 * stage iv cancer/metastatic disease exclusion criteria: * expected life expectancy \< 3 months * inability to undergo stent insertion * siewert type iii gastroesophageal cancer * esophageal-airway fistula

Keywords: dysphagia esophagus cancer esophageal cancer
association between vitamin d deficiency and preeclampsia: a case control study

Conditions: Pre-Eclampsia

Summary: to find out if lower levels of vitamin d is more prevalent in preeclamptic women


Eligibility criteria:
inclusion criteria: * parity: primigravida. * age: 18 - 35 years. * singleton pregnancy. * gestational age: 36-40 weeks. * no past history of any medical disorder and with no other medical complications during pregnancy exclusion criteria: * women with preexisting medical conditions like rheumatoid arthritis, thyroid, hepatic or renal failure, metabolic bone disease, diabetes mellitus, malabsorption and lupus. * history of intake of medications influencing bone, vitamin d or calcium metabolism e.g. antiepileptic, theophylline, antitubercular drugs in the last 6 months. * women with multiple pregnancy. * women with congenital fetal malformation. * women with known thrombophilia
mri study of the structural and functional rehabilitation in the cerebral infarction patients with diabetes

Conditions: Cerebral Stroke; Diabetes Mellitus

Summary: diabetes mellitus (dm) plays an important role in the occurrence of the cerebral infarction (ci). clinical studies have demonstrated that the ci patients with dm had a poor prognosis compared with those without dm. previous magnetic resonance imaging (mri) studies have shown that patients with dm had abnormalities in cerebral vessels, nerves and functions, similar with the findings in mice models. in this study, with multi-modal mri technologies, investigators tend to observe structural and functional changes of the brain in both dm and non-dm ci patients and assess their neural rehabilitation using clinical scales in the following 6 months. investigators also expect to find out dynamic changes of brain structure and function, to reveal the weights of factors including brain blood vessels, nerves and function remodeling related with stroke recovery, as well as the potential mechanism in ci patients with dm.


Eligibility criteria:
inclusion criteria: 1. ﬁrst-ever ischemic stroke; 2. single infarct in the distribution of the middle cerebral artery; 3. no evidence of hemorrhagic infarction; 4. age greater than 18 years; 5. admission between 3 and 7 days after stroke onset; 6. national institute of health stroke score (nihss) score of 4 to 21 on admission and 7. no thrombolytic or recanalization therapies. exclusion criteria: 1. atrial fibrillation; 2. history of neurological or psychiatric disorders; 3. pre-stroke modified rankin scale (mrs) \> 1; 4. life expectancy \< 1 year.

Keywords: cerebral infarction diabetes rehabilitation mri
erector spinae plane block for postoperative pain in percutaneous nephrolithotomy patients: a retrospective study

Conditions: Percutaneous Nephrolithotomy

Summary: to evaluate the ability of erector spina plane block decrease postoperative pain and analgesia requirements in patients undergoing percutaneous nephrolithotomy.

erector spina plane block was performed with guided ultrasound at t10 transverse process level would lead to adequate postoperative analgesia ,in percutaneous nephrolithotomy surgeries.

Eligibility criteria:
inclusion criteria: * asa i- asa ii patients exclusion criteria: * history of allergy to the study medication * refusal to participate

Keywords: erector spinae block percutaneous nephrolithotomy stone ultrasound
gastric modulator (tantalus® system) versus insulin treatment in obese type 2 diabetic patients - a randomized control trial

Conditions: Type 2 Diabetes Mellitus

Summary: this study aims to analyze the pre- and post-operative clinical, hormonal and biochemical changes in moderately obese type 2 diabetic patients who are sub-optimally controlled on at least 2 anti-diabetic agents. study participants will either receive implantation of the gastric contraction modulator or conventional treatment with insulin therapy.


Eligibility criteria:
inclusion criteria: * able to provide written informed consent * adult patients aged between 18 and 60 years (inclusive) * male or female of chinese ethnicity * type 2 diabetes mellitus with disease duration of greater than 2 and less than 10 years * severe obesity, includes bmi 25 to 27.5 kg/m and central obesity defined by waist circumference greater than 90 cm in women and greater than 95 in men, or bmi greater than 27.5 to less than 35 kg/m * hba1c greater than or equals to 7.5% but less than 10% despite treated with maximum dose or maximally tolerated dose of 2 anti-diabetic drugs (oad) with good drug compliance exclusion criteria: * on anti-obesity drugs * on insulin treatment at the time of the recruitment * on glitazone or incretins (dipeptidyl peptidase-4 inhibitor or glucagons-like peptide-1) treatment * on any implantable device including cardiac pacing * anticipated to have mri examinations * fasting c-peptide level less than 0.5g/l * renal impairment (defined as serum creatinine greater than 150mol/l and/or estimated glomerular filtration rate less than 60 ml/min/1.73m) * significant liver impairment (alt more than 3 times upper limit of normal range) * active malignant disease. patients with malignant disease who have been disease-free for at least 5 years are eligible * active infection * active and uncontrolled thyroid diseases * childbearing age female patients without reliable contraceptive methods * life expectancy less than 12 months * administration of another investigational drugs or procedures within 4 weeks before screening * any medical illness or condition as judged by the investigators as ineligible to participate the study * special population, e.g. prisoner, mentally disabled, investigators' student or employees

Keywords: type 2 diabetes mellitus obesity